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ABSTRACT
Background: Patients with advanced heart failure may continue for prolonged times with persistent he-
modynamic abnormalities; intermediate- and long-term outcomes of these patients are unknown.
Methods and Results: We used ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary
Artery Catheterization Effectiveness) trial data to examine characteristics and outcomes of patients with
invasive hemodynamic monitoring during an acute heart failure hospitalization. Patients were stratified by
final measurement of cardiac index (CI; L/min/m2) and pulmonary capillary wedge pressure (PCWP; mmHg)
before catheter removal. The study groups were CI ≥ 2/PCWP < 20 (n = 74), CI ≥ 2/PCWP ≥ 20 (n = 37),
CI < 2/PCWP < 20 (n = 23), and CI < 2/PCWP ≥ 20 (n = 17). Final CI was not associated with the com-
bined risk of death, cardiovascular hospitalization, and transplantation (hazard ratio [HR]1.03, 95% confidence
interval 0.96–1.11 per 0.2 L/min/m2 decrease, P = .39), but final PCWP ≥ 20 mmHg was associated with
increased risk of these events (HR 2.03, 95% confidence interval 1.31–3.15, P < .01), as was higher final
right atrial pressure (HR 1.09, 95% confidence interval 1.06–1.12 per mmHg increase, P < .01).
Conclusion: Final PCWP and final right atrial pressure were stronger predictors of postdischarge out-
comes than CI in patients with advanced heart failure. The ability to lower filling pressures appears to be
more prognostically important than improving CI in the management of patients with advanced heart failure.
ClinicalTrials.gov Identifier: NCT00000619 (J Cardiac Fail 2016;22:182–189)
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In the United States, heart failure affects more than 5 million
people and results in more than 1 million hospitalizations per
year.1 In patients age 65 years and older, there are more hos-
pitalizations for a primary diagnosis of heart failure than any
other condition.2 Although many patients have evidence of
poor perfusion on admission,3 volume overload is the most
common reason for hospitalization for heart failure.4–6 Even
with inpatient treatment, many patients are discharged with
signs and symptoms of persistent congestion.4 Despite optimal
therapy for heart failure, morbidity and mortality following
hospitalization remain high.6,7
Invasive hemodynamic measurements of cardiac index
(CI) and left ventricular filling pressure are commonly used
to characterize the clinical phenotype of patients with ad-
vanced heart failure. Patients with heart failure may remain
in a hemodynamic state consistent with cardiogenic shock
and congestion for prolonged periods. However, data on the
impact of persistent hemodynamic abnormalities are limited.
The Evaluation Study of Congestive Heart Failure and Pul-
monary Artery Catheterization Effectiveness (ESCAPE) trial
enrolled patients hospitalized for acute heart failure, with at
least 1 sign and 1 symptom of congestion, and collected
information from invasive hemodynamic assessments. The
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ESCAPE data provide an ideal population from which to
assess associations between hemodynamic measurements
and outcomes. Therefore, we examined morbidity and mor-
tality outcomes of patients with advanced heart failure based




The ESCAPE trial was a multicenter, randomized con-
trolled trial evaluating the effectiveness of pulmonary artery
catheter (PAC) in the management of patients hospitalized
with severe symptomatic heart failure with reduced ejection
fraction. The trial was conducted at 26 sites from 2000 to
2003. Patients were eligible for the study if they had 3
months of symptoms despite treatment with an angiotensin-
converting enzyme inhibitor and diuretics and had at least 1
sign and 1 symptom of congestion. Patients were required
to have a left ventricular ejection fraction ≤30% and sys-
tolic blood pressure ≤125 mmHg. Exclusion criteria included
creatinine level ≥3.5 mg/dL, prior use of dobutamine or
dopamine ≥3 μg/kg/min, or prior use of milrinone during
hospitalization. A total of 433 patients from 26 centers were
randomized to receive therapy guided by clinical assess-
ment alone or clinical assessment and data from a PAC. Of
the 215 patients randomized to PAC, 141 (65.6%) had com-
plete hemodynamic and follow-up data at 6 months and
were included in this analysis. Ten patients who were not
randomized to PAC had hemodynamic data and were in-
cluded in this analysis. Hemodynamic measurements from
the PAC were recorded at baseline and serially at least
twice daily until the catheter was removed (median 48 hours).
All hemodynamic measurements were performed at rest.
Follow-up occurred after hospital discharge at 1–2 weeks,
then at 1, 2, 3, and 6 months. The primary endpoint was
days to death, cardiac transplantation, or cardiac hospital-
ization in the 6 months following randomization. Results of
the ESCAPE trial have been published previously.8
Classification and Definitions
For the present study, we included patients with com-
plete hemodynamic data and follow up (N = 151). Treatment
goals in the PAC group included resolution of signs and
symptoms of congestion, pulmonary capillary wedge pres-
sure (PCWP) ≤15 mmHg, and right atrial pressure ≤8 mmHg.
Final measurements were defined as the last recorded
measurements prior to PAC removal. Patients were strati-
fied by final measurements of CI (CI < 2, CI ≥ 2 L/min/m2)
and pulmonary capillary wedge pressure (PCWP < 20,
PCWP ≥ 20 mmHg). The cutoffs for CI and PCWP were
chosen to reflect the severity of poor perfusion and conges-
tion in this patient population and have been used previously
to define shock or the need for invasive hemodynamic
monitoring.9,10
Statistics
Demographics, physical and laboratory findings, medical
history, and therapies were summarized as frequencies and
percentages for categorical variables and by the medians with
25th and 75th percentiles for continuous variables. Baseline
characteristics were compared using the Kruskal-Wallis test
for continuous variables, and chi-square or Fisher’s exact tests
for categorical variables. Event rate curves for the primary
endpoint in the 4 hemodynamic groups were shown using un-
adjusted Kaplan-Meier estimates and compared with log-
rank tests. Relationships between baseline characteristics or
hemodynamic measurements and 6-month mortality, cardio-
vascular hospitalization, or transplant were tested with
univariable Cox proportional hazards regression models.
Hazard ratios (HRs) with corresponding 95% confidence in-
tervals are presented for baseline and final hemodynamic
measures as well as significant baseline patient characteris-
tics. Statistical significance was assessed using 2-sided P
values. A P value < .05 was considered statistically signifi-
cant. All statistical computations were generated using SAS,
version 9.2 (SAS Institute Inc., Cary, North Carolina).
Results
Table 1 shows the baseline characteristics of the study
population. Of 151 patients, 74 (49.0%) had final CI ≥ 2/
PCWP < 20 (warm and dry), 37 (24.5%) had final CI ≥ 2/
PCWP ≥ 20 (warm and wet), 23 (15.2%) had final
CI < 2/PCWP < 20 (cold and dry), and 17 (11.3%) had final
CI < 2/PCWP ≥ 20 (cold and wet). Patients with the most ab-
normal final hemodynamic measurements (low CI and high
PCWP) were more likely to have ischemic etiology and other
comorbidities including peripheral vascular disease, cerebro-
vascular disease, and diabetes. They also had the shortest
baseline 6-minute walk distance compared with the other
groups. Those with a persistently reduced CI were older, and
there was a higher percentage of female patients with per-
sistently reduced CI than with a normal final CI. Patients with
a final PCWP < 20 mmHg were more likely to be female, non-
white, and have higher baseline blood pressure and lower
baseline creatinine.
Patients with a low CI and high PCWP at the end of the
study had the highest right atrial pressure, pulmonary artery
pressure, and PCWP at baseline. Conversely, patients with
the most favorable final hemodynamic measurements (higher
CI and lower PCWP) were most likely to have a lower right
atrial pressure, pulmonary artery pressure, and PCWP at base-
line (Fig. 1, Table 2). Patients with an elevated final PCWP
had higher baseline right atrial pressure, pulmonary artery pres-
sure, and PCWP compared with patients with a lower final
PCWP. Patients with residual low CI had a higher baseline
right atrial pressure and PCWP, and lower baseline CI, re-
gardless of final PCWP.
Supplemental Tables S1 and 2 show pairwise compari-
sons between those with CI < 2 and CI ≥ 2 and those with
PCWP < 20 and PCWP ≥ 20 for baseline characteristics and
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Table 1. Baseline Characteristics of the Study Population*
Preserved Cardiac Index (≥2 L/min/m2) Reduced Cardiac Index (<2 L/min/m2)
Variable PCWP < 20 (n = 74) PCWP ≥ 20 (n = 37) PCWP < 20 (n = 23) PCWP ≥20 (n = 17) P
Age, y 56 (47–66) 54 (49–66) 67 (49–71) 60 (49–64) .45
Gender, female 23 (31.1) 5 (13.5) 12 (52.2) 5 (29.4) .02
Race, non-white 34 (45.9) 10 (27.0) 13 (56.5) 5 (29.4) .07
Ischemic etiology 35 (47.3) 20 (54.1) 12 (52.2) 13 (76.5) .19
Medical history
Angina pectoris 28 (37.8) 10 (27.0) 3 (13.0) 8 (47.1) .07
Myocardial infarction 32 (43.2) 22 (59.5) 8 (34.8) 12 (70.6) .05
PCI 16 (21.6) 11 (29.7) 5 (21.7) 8 (47.1) .17
CABG 19 (25.7) 14 (37.8) 5 (21.7) 5 (29.4) .49
Peripheral vascular disease 7 (9.5) 5 (13.5) 2 (8.7) 6 (35.3) .06
COPD 11 (14.9) 5 (13.5) 5 (21.7) 4 (23.5) .67
Diabetes 21 (29.2) 12 (33.3) 7 (30.4) 7 (41.2) .81
Hypertension 37 (50.0) 18 (48.6) 11 (47.8) 7 (41.2) .93
ICD 21 (28.4) 11 (29.7) 4 (17.4) 4 (23.5) .71
Atrial fibrillation 17 (23.0) 17 (45.9) 8 (34.8) 5 (29.4) .10
Ventricular tachycardia/fibrillation 11 (14.9) 8 (21.6) 3 (13.0) 3 (17.6) .79
Cerebrovascular disease 8 (10.8) 7 (18.9) 5 (21.7) 4 (23.5) .31
Renal insufficiency† 5 (6.8) 3 (8.1) 0 (0) 1 (6.7) .68
Physical examination
BMI, kg/m2 27.9 (23.9–33.5) 27.7 (24.1–33.4) 24.4 (21.3–28.4) 28.4 (24.2–32.1) .12
Baseline heart rate, bpm 81 (70–93.5) 79 (72–88) 84 (76–93) 74.5 (64.5–93) .37
Baseline SBP, mmHg 109 (95–120) 98 (94–108) 110 (99–125) 98 (90–116) .05
Baseline DBP, mmHg 68 (60–76) 64 (57–70) 70 (61–84) 64 (58–70) .17
Baseline testing
Baseline EF, % 20 (15–25) 20 (15–22) 15 (15–20) 19 (15–20) .07
6-min walk distance, feet 249 (0–650) 390 (0–650) 360 (0–650) 50 (0–725) .80
Sodium, mEq/L 137 (136–140) 136 (134–139) 138 (136–141) 136 (131–138) .05
Creatinine, mg/dL 1.4 (1–1.8) 1.6 (1.3–2) 1.3 (1–1.5) 1.5 (1.2–2) .12
BUN, mg/dL 27 (17–41) 33 (24–51) 25 (20–31) 31 (28–43) .12
ALT, units/L 25.5 (18–37.5) 24 (18–34) 34 (22–59) 24 (22–38) .43
AST, units/L 29 (21–41) 27 (22–34) 30 (24–49) 29 (25–31) .61
Albumin, g/dL 3.5 (3.3–3.8) 3.8 (3.30–4.10) 3.4 (3.1–3.7) 3.7 (3.5–3.9) .18
Total bilirubin, mg/dL 0.7 (0.40–1.10) 1.1 (0.6–1.4) 1.1 (0.70–1.40) 0.4 (0.3–1.1) .02
*Presented as N (%) or median (25th, 75th percentile).
†Medical history of renal insufficiency defined as history of creatinine >3.5 mg/dL or history of chronic dialysis. Current creatinine >3.5 mg/dL was an
exclusion criterion for the study.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive
pulmonary disease; DBP, diastolic blood pressure; EF, ejection fraction; ICD, implantable cardioverter defibrillator; PCI, percutaneous coronary interven-
tion; PVD, peripheral vascular disease; SBP, systolic blood pressure.
Fig. 1. Bar graph of baseline and final median hemodynamic pressure and cardiac index (CI) measurements by group. (A) The median base-
line and final hemodynamic pressure measurements for patients stratified by final hemodynamic measurements. (B) The median baseline
and final CI measurements for patients stratified by final hemodynamic measurements. PA, pulmonary artery; PCWP, pulmonary capillary
wedge pressure; RA, right artery.
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hemodynamic measurements, and medication use, respec-
tively. Supplemental Table S3 presents medication use in the
patient groups stratified by hemodynamic profiles. The
hemodynamic profile was not significantly associated with
baseline medications, drugs used during the hospitalization,
or discharge medications.
Supplemental Table S4 presents in-hospital complica-
tions and procedures. Few patients experienced in-hospital
complications or underwent cardiac procedures. Although pa-
tients with a high PCWP and normal CI were more likely to
have ventricular tachyarrhythmias and receive cardiopulmo-
nary resuscitation and cardioversion, those with a high PCWP
and low CI were most likely to have ischemia or angina and
receive mechanical circulatory support (MCS) with intra-
aortic balloon pump or left ventricular assist device.
In follow-up, 34 patients died, 60 were rehospitalized, and
9 underwent cardiac transplantation (Table 3). Variables as-
sociated with increased risk of mortality, cardiovascular
hospitalization, or cardiac transplant included abnormal base-
line and final right- and left-sided filling pressures, abnormal
renal function, and chronic obstructive pulmonary disease,
whereas variables associated with decreased risk of adverse
events included higher baseline sodium, higher baseline
blood pressure, and angiotensin-converting enzyme inhibitor
use (Fig. 2). Final CI was not associated with the combined
risk of death, cardiovascular hospitalization, or cardiac
transplantation (HR 1.03, 95% confidence interval 0.96–1.11
per 0.2 L/min/m2 decrease, P = .39). Conversely, final
PCWP ≥ 20 mmHg was univariably associated with increased
morbidity and mortality (HR 2.03, 95% confidence interval
1.31–3.15, P < .01), as was final right atrial pressure (HR 1.09,
95% confidence interval 1.06–1.12 per mmHg increase, P < .01).
Figure 3 presents the unadjusted association between final he-
modynamic measurements and the combined outcomes of death,
cardiac hospitalization, and cardiac transplantation.
Discussion
The role of hemodynamic perturbation is central to our un-
derstanding of heart failure physiology. Reduced contractility
leads to reduced stroke volume, which in turn leads to in-
creased heart rate, increased filling pressures, and increased
vasoconstriction. These compensatory mechanisms become
maladaptive and ultimately lead to increased myocardial
oxygen demand and worsening cardiac function.11 In its most
advanced stages, heart failure is characterized by elevated in-
tracardiac filling pressures, peripheral vasoconstriction, and
Table 2. Baseline and Final Hemodynamics of the Study Population*
Preserved CI (≥2 L/min/m2) Reduced CI (<2 L/min/m2)
Variable PCWP < 20 (n = 74) PCWP ≥ 20 (n = 37) PCWP < 20 (n = 23) PCWP ≥ 20 (n = 17) P
Baseline hemodynamics
RAP, mmHg 10 (6–15) 12 (8–20) 13 (8–18) 17 (12.5–20) .01
PA mean, mmHg 33 (26–41) 39 (33–46) 34.5 (32–44) 45 (31.5–49) .04
CI, L/min/m2 2.0 (1.8–2.4) 2.1 (1.7–2.4) 1.5 (1.2–1.8) 1.6 (1.4–1.9) <.001
CO, L/min 3.9 (3.1–4.7) 4 (3.6–5.1) 2.9 (2.4–3.2) 3.23 (2.7–4.0) <.001
SVR, dynes × sec/cm2 1322 (1116–1631) 1162 (921–1440) 1923 (1350–2088) 1546 (1464–2003) <.001
PCWP, mmHg 22 (16–27) 25 (21–36) 25.5 (20–30) 28.5 (24–33.5) <.001
Final hemodynamics
RAP, mmHg 6 (4–10) 11 (9–15) 5 (4–8) 12 (9–20) <.001
PA mean, mmHg 25.5 (22–30) 33.5 (30–39) 23 (20–32) 38 (33–40) <.001
CI, L/min/m2 2.6 (2.2–2.8) 2.5 (2.3–2.9) 1.73 (1.5–1.9) 1.60 (1.5–1.9) By definition
CO, L/min 4.81 (4.3–5.6) 5.10 (4.58–5.9) 3.18 (2.61–3.6) 3.3 (2.8–3.9) <.001
SVR, dynes × sec/cm2 1083 (813–1207) 867 (568–1022) 1735 (1490–1903) 1446 (1213–1748) <.001
PCWP, mmHg 14 (10–17) 22 (21–24) 13 (11–15) 26 (23–30) By definition
*Presented as median (25th, 75th percentile).
CI: cardiac index, CO: cardiac output, PA: pulmonary artery, PCWP: pulmonary capillary wedge pressure, RAP: right atrial pressure, SVR: systemic venous
resistance.
Table 3. Follow-up Outcomes of Study Population
Final Hemodynamics Death Cardiovascular Hospitalization Heart Transplant
CI ≥ 2 L/min/m2, PCWP < 20 mmHg (n = 74) 10 (13.5%) 23 (31.1%) 3 (4.1%)
CI ≥ 2 L/min/m2, PCWP ≥ 20 mmHg (n = 37) 12 (32.4%) 20 (54.1%) 4 (1.1%)
CI < 2 L/min/m2, PCWP < 20 mmHg (n = 23) 5 (21.7%) 11 (47.8%) 1 (4.3%)
CI < 2 L/min/m2, PCWP ≥ 20 mmHg (n = 17) 7 (41.2%) 6 (35.3%) 1 (5.9%)
All PCWP < 20 mmHg (N = 97) 15 (15.5%) 34 (35.1%) 4 (4.1%)
All PCWP ≥ 20 mmHg (N = 54) 19 (35.2%) 26 (48.1%) 5 (9.3%)
All CI ≥ 2 L/min/m2 (N = 111) 22 (19.8%) 43 (38.7%) 7 (6.3%)
All CI < 2 L/min/m2 (N = 40) 12 (30.0%) 17 (42.5%) 2 (5.0%)
CI: cardiac index, PCWP: pulmonary capillary wedge pressure.
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decreased cardiac output. These hemodynamic alterations in-
directly form the basis of targeted pharmacotherapy. Although
hemodynamic abnormalities in heart failure may persist despite
optimal medical treatment, data on the impact of persistent
hemodynamic abnormalities on intermediate-term morbidi-
ty and mortality outcomes are limited.5,12,13 We demonstrate
that baseline hemodynamics tend to predict the hemody-
namic profile following medical therapy. More importantly,
persistently elevated right- and left-sided filling pressures in
patients with heart failure during a heart failure hospitaliza-
tion is predictive of the combined risk of death, cardiovascular
hospitalization, and heart transplantation whereas resting CI
has less prognostic utility.
In this study, the combined primary endpoint was driven
by rehospitalizations, which accounted for more than half of
the events. Furthermore, the mortality rate for those with per-
sistent congestion was more than double that of patients who
achieved adequate congestion. Persistent congestion and symp-
toms may have been the basis for the rehospitalizations, given
that most patients hospitalized with heart failure present with
dyspnea.7 Taken in the context of prior studies that have shown
that hospitalizations are associated with increased mortality
in the heart failure population and that the risk of death in-
creases with repeated hospitalizations, these findings highlight
the importance assessing for and managing congestion in pa-
tients with acute heart failure.14–16
Prior studies that have shown that the presence of conges-
tion is associated with adverse outcomes, including heart failure
hospitalization and death.3,10,17–20 It is also recognized that a
significant proportion of patients hospitalized for volume over-
load are inadequately decongested at the time of discharge,
and persistent congestion is associated with worse
outcomes.12,21 In addition, prior work has shown that a change
in CI with treatment is not predictive of poor outcomes.10,13
Our findings confirm these prior findings using invasive he-
modynamic data. Furthermore, by categorizing patients by
both PCWP and CI, we extend the prior findings by showing
that congestion is associated with worse outcomes indepen-
dent of CI.
Although we found that resting CI is not associated with
outcomes, prior work has shown that using resting CI in con-
junction with exercise testing is predictive of outcomes.22–24
Fig. 2. Univariate associations with death or cardiac hospitalization or cardiac transplant. ACE, angiotensin-converting enzyme; BP, blood
pressure; BUN, blood urea nitrogen; CI, cardiac index; COPD, chronic obstructive pulmonary disease; PA, pulmonary artery; PCWP, pul-
monary capillary wedge pressure; RAP, right atrial pressure.
Fig. 3. Kaplan-Meier estimates of freedom from death, cardiac hospitalization, and cardiac transplantation. (A) The Kaplan-Meier esti-
mates of freedom from death, cardiac hospitalization, and cardiac transplantation for patients with final cardiac index (CI) < 2 L/min/m2
and final CI ≥ 2 L/min/m2. (B) The Kaplan-Meier estimates of freedom from death, cardiac hospitalization, and cardiac transplantation for
patients with final pulmonary capillary wedge pressure (PCWP) < 20 mmHg and final PCWP ≤ 20 mmHg. (C) The Kaplan-Meier estimates
of freedom from death, cardiac hospitalization, and cardiac transplantation for patients with final CI ≥ 2 L/min/m2 and PCWP ≥ 20 mmHg,
CI ≥ 2 L/min/m2 and PCWP < 20 mmHg, CI < 2 L/min/m2 and PCWP ≥ 20 mmHg, and CI < 2 L/min/m2 and PCWP < 20 mmHg.
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In our study, it appears that congestion is the driver of adverse
outcomes in this patient population; however, low CI likely
contributes in that it may be more difficult to achieve ade-
quate diuresis in patients with a low CI. Notably, patients with
persistent congestion had lower blood pressure and worse renal
function at baseline. Poor perfusion may lead to impaired renal
function, which limits the bioavailability of diuretics; fur-
thermore, hypoperfusion resulting from low blood pressure
often reduces the tolerability of decongestion and vasodila-
tor strategies.
The downstream effects of congestion on other organs may
be another mechanism by which persistently congested pa-
tients have worse outcomes. Several studies have shown
interactions between renal function and congestion. Prior work
from Metra and colleagues showed persistent congestion in
the setting of worsening renal function in acute heart failure
was associated with worse outcomes compared with wors-
ening renal function alone.25 Additionally, in a prior analysis
from ESCAPE, renal insufficiency at baseline and dis-
charge were associated with increased risk of death and
rehospitalization. The results could not be explained by low
cardiac output; however, a correlation between right atrial pres-
sure and renal function was noted, suggesting that elevated
filling pressures may have played a role.26
Despite the differences, patients with low final PCWP and
high final PCWP were treated similarly with regard to base-
line, in-hospital, and discharge medications. Relatively few
patients experienced in-hospital complications or under-
went cardiac procedures to treat low CI or elevated intracardiac
filling pressures. This may reflect the lack of supportive treat-
ments that result in sustained improvements in CI during the
period the ESCAPE study was conducted. Although inotropes
can temporarily augment cardiac output, they provide no long-
term positive effects on cardiac recovery or remodeling, and
are associated with increased mortality.27–29 And although tem-
porary MCS can help sustain a patient in the short-term, the
benefits do not persist once the device is removed.30,31 Fur-
thermore, availability of durable MCS as a long-term therapy
did not develop until after completion of ESCAPE.32–35 Al-
though there is a paucity of short-term treatment strategies
to improve long-term CI, it appears, based on this study, that
the driver of outcomes is not in the ability to improve CI, but
to improve filling pressures.
Initiation of inotropic support and referral for consider-
ation of advanced heart failure therapies is often driven by
low CI and advanced therapies may be withheld in the setting
of preserved CI. However, congestion, regardless of CI, may
be an additional target for agents that increase contractility
or devices that directly unload the left ventricle to lower PCWP.
Clinical Implications
Results of this analysis confirm that many patients have
persistent hemodynamic abnormalities despite treatment aimed
at reversing these abnormalities. Although persistently low
CI and persistently high PCWP or high right atrial pressure
are all associated with poor outcomes, it appears that persistent
volume overload is a stronger predictor of worse outcomes
in a heart failure population compared with CI.
Importantly, though invasive hemodynamic testing was used
to determine hemodynamic profiles in this study, clinician
assessments of hemodynamics based on history and physi-
cal examination findings have also been shown to predict
outcomes.3,17,36 Therefore, these results may be able to be
extended to patients without invasive hemodynamic
measurements.
In the care of patients with advanced heart failure, choos-
ing when to abort temporary measures, such as inotropes or
temporary mechanical support, for more permanent solu-
tions, such as durable LVADs or transplantation, can be a
difficult decision. This study suggests that the inability to ef-
fectively achieve a more normal intravascular volume status
may be a harbinger of poor outcomes; therefore, persistent
congestion may represent an important clinical sign that in
addition to other clinical characteristics may help to inform
the decision on when to move forward with advanced heart
failure therapies.
Limitations
There are several limitations of this study. First, this study
was a retrospective analysis. Second, only 151 patients in the
ESCAPE trial had complete hemodynamic data and thor-
ough follow-up, limiting the sample size for the study. Given
the overall limited sample size, the number of patients in each
group was small. Furthermore, because of the small sample
size and few number of events, a multivariable analysis could
not be done. Third, although most patients hospitalized for
heart failure have congestion, the entry criteria for this trial
required it, so patients were only included in this study if they
had 1 sign and 1 symptom of congestion, potentially influ-
encing the importance of congestion for prognosis in this cohort.
Furthermore, patients with worse final hemodynamics may
have been more likely to be referred to transplant or had a
lower threshold for rehospitalization given that it was known
that they were sicker. Fourth, the ESCAPE trial was de-
signed to evaluate an acute heart failure population in which
there was clinical equipoise with regard to PAC use. There-
fore, patients deemed “too sick” or “too well” were not included.
It is possible that persistent hemodynamic derangements have
different effects on outcomes for those patients not captured
in the trial. Also, treatment strategies were not specified in
the trial. Although all centers participating in the ESCAPE
trial were experienced in the management of advanced heart
failure, patients may have received different treatments for
similar hemodynamic profiles. Finally, treatment options for
the advanced heart failure population has changed in the time
between the ESCAPE trial and this analysis, specifically with
the increased use of durable MCS devices.
Conclusion
Time to death, cardiovascular hospitalization, or trans-
plant was not influenced by CI, whereas elevated right- and
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left-sided filling pressures were associated with this end-
point. PCWP was a stronger predictor of worse outcomes than
CI in patients with advanced heart failure within 6 months
of hospitalization. Our study suggests the ability to lower filling
pressures appears to be more prognostically important than




Disclaimer: The content is solely the responsibility of the
authors and does not necessarily represent the official views
of the National Institutes of Health.
Supplementary Data
Supplementary data to this article can be found online at
doi:10.1016/j.cardfail.2015.11.012.
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